Posted in Biotech, Genzyme, Novartis, Pharma, Pharma News, Pharmaceutical, Sanofi-Aventis, Top News, tagged fosamax, Genzyme, Gilead sciences, Multaq, Reclast on March 25, 2010 |
What about those bone fracture risks with biophosphonate drugs? The jury is still out – A new study gives reassuring news about the safety of Fosamax and Reclast, bone-building drugs taken by millions of American women. It found that long-term use does not significantly raise the risk of a rare type of fracture near the hip…more
Monthly hepatitis C treatment looking promising – Human Genome Sciences Inc. said Wednesday a midstage study of the potential hepatitis C treatment Zalbin showed a monthly dose of the drug candidate could be as effective as a weekly dose of the standard treatment. The Rockville, Md., company said interim results from the study support evaluation of the monthly dose in a bigger, late-stage trial. The midstage study was conducted by Novartis, which is developing the drug with Human Genome Sciences. It combined the drug with ribavirin in 391 patients with forms of chronic hepatitis C…more
Massive Multaq Mess Might Mean Major Meltdown – The scale of Sanofi-Aventis (SNY)’s Multaq mess is starting to become apparent: The heart drug, hailed by the company as a €1 billion-plus blockbuster prior to its launch, may miss Wall Street sales estimates by as much as €1.3 billion, according to analysts at Jefferies International. When investors wake up and downgrade their expectations for the atrial fibrillation drug, Sanofi’s stock may suffer, they say…more
Genzyme – feeling fines.
Employee Assessment – including Executive Management assessment – Impactiviti’s vendor/partners have just what you need for top assessment programs and services. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
Another reason to like Gilead Sciences (besides the fact that they have the best logo in the industry) – they actually have a rational pay plan for their top executive. What would it look like if pharma upper executive pay were based on annual performance for these measures: Profitability ratio (earnings vs. # of employees – something Gilead excels at, by the way); company share increase over a 3-year running average; and regulatory compliance? We might then see real pay-for-performance!
JUST FOR FUN
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Visit the Impactiviti Job Board
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
Read Full Post »
Posted in Eli Lilly, Ethics, FDA, Glaxosmithkline, GSK, J&J, Johnson and Johnson, Lilly, Marketing, Novartis, Oncology, Pharma, Pharma News, Pharmaceutical, Scandal, Top News, tagged Eli Lilly, Gilead sciences, GSK, J&J, Merck, Pfizer on February 23, 2010 |
Big approval news for Gilead Sciences – Gilead Sciences Inc., the world’s largest maker of HIV treatments, won U.S. approval of an inhaled antibiotic for lung infections in cystic fibrosis patients. The Food and Drug Administration cleared sales of the medicine, given the brand name Cayston, the company said today in a statement. Outside advisers to the FDA backed the product’s safety and effectiveness in a 15-2 vote on Dec. 10…more
What is the future of “personalized medicine”? Probably, it’ll look a lot like this (encouraging story from NY Times). Plus, in a cooperative effort, Eli Lilly, Merck and Pfizer have formed an independent, not-for-profit company Asian Cancer Research Group (ACRG) to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia…more
Of course, in this industry, there is often a mix of good news and bad – and “bad” usually means bad behavior by people who love dollars above sense: lack of openness at AZ?; secret tapes and GSK (plus, a “fixer” who spiked research?); research fraud by rogue doc; kickbacks and J&J; risk of depression assessment and Eli Lilly (are you alive? then you’re at risk!!!). Reminds me of some prior posts on the Gold-in Rule…
Novartis looking to expand even more at East Hanover campus. Including themed food venues!
Marketing Training – Looking for resources for training brand marketing professionals? We know the providers you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for vendor recommendations.
I’m feeling much safer now. FDA finally comes out against “ear candling“! Next up, perhaps – a prohibition of USB-to-nasal-passage uploads??
JUST FOR FUN
Read Full Post »
Posted in Genentech, Medicine, Pfizer, Pharma, Pharma News, Pharmaceutical, Top News, tagged Avastin, Gilead sciences, Toviaz on April 3, 2009 |
Avastin approved for glioblastoma.
Nice results for experimental blood pressure drug from Gilead – Gilead Sciences Inc said on Thursday its experimental drug to treat patients whose high blood pressure is not controlled by other medicines met both the primary goals of a late-stage study, sending its shares 5 percent higher. “In this study, more than half of the patients treated with darusentan achieved goal blood pressure, as compared to approximately one quarter of patients receiving placebo,” Gilead’s research chief Norbert Bischofberger said in a statement.
Pfizer launching Detrol replacement (Toviaz). The most interesting part of the article is what it has to say about less dependence on sales reps for promotion. As the clock ticks down on patents for Pfizer’s $1.2 billion blockbuster drug Detrol, the drug giant is launching a new one to take its place: overactive-bladder remedy Toviaz. The idea is to educate patients while freeing up physicians’ time — and reducing the need for a large sales force. Jim Maffezzoli, senior director-marketing in Pfizer’s new primary-care unit, which is marketing the drug, said the sales force will be “significantly smaller” than before and will be retrained to become more of a partner to physicians and understand their needs.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
Read Full Post »